Barbara Donner

Summary

Affiliation: F. Hoffmann-La Roche Ltd

Publications

  1. doi request reprint Safety of oseltamivir in pregnancy: a review of preclinical and clinical data
    Barbara Donner
    F Hoffmann La Roche, Basel, Switzerland
    Drug Saf 33:631-42. 2010
  2. doi request reprint Safety profile of oseltamivir during the 2009 influenza pandemic
    Barbara Donner
    F Hoffmann La Roche Ltd, Basel, Switzerland
    Pharmacoepidemiol Drug Saf 20:532-43. 2011
  3. doi request reprint Post-marketing assessment of neuropsychiatric adverse events in influenza patients treated with oseltamivir: an updated review
    Stephen Toovey
    F Hoffmann La Roche Ltd, PBMT Bldg 74 3O Z01 05, CH 4070, Basel, Switzerland
    Adv Ther 29:826-48. 2012
  4. doi request reprint Absence of central nervous system and hypothermic effects after single oral administration of high doses of oseltamivir in the rat
    Christian Freichel
    F Hoffmann La Roche Ltd, Basel, Switzerland
    Basic Clin Pharmacol Toxicol 111:50-7. 2012
  5. doi request reprint Oseltamivir in seasonal, pandemic, and avian influenza: a comprehensive review of 10-years clinical experience
    James R Smith
    Pharmaceuticals Division, F Hoffmann La Roche Ltd, PBMT Bldg 74 3O Z1 06, CH 4070, Basel, Switzerland
    Adv Ther 28:927-59. 2011
  6. doi request reprint Assessment of neuropsychiatric adverse events in influenza patients treated with oseltamivir: a comprehensive review
    Stephen Toovey
    F Hoffmann La Roche Ltd, Basel, Switzerland
    Drug Saf 31:1097-114. 2008

Collaborators

Detail Information

Publications6

  1. doi request reprint Safety of oseltamivir in pregnancy: a review of preclinical and clinical data
    Barbara Donner
    F Hoffmann La Roche, Basel, Switzerland
    Drug Saf 33:631-42. 2010
    ..Roche will continue to monitor all reports of oseltamivir use during pregnancy...
  2. doi request reprint Safety profile of oseltamivir during the 2009 influenza pandemic
    Barbara Donner
    F Hoffmann La Roche Ltd, Basel, Switzerland
    Pharmacoepidemiol Drug Saf 20:532-43. 2011
    ..This study evaluated the safety of oseltamivir during the 2009 influenza pandemic...
  3. doi request reprint Post-marketing assessment of neuropsychiatric adverse events in influenza patients treated with oseltamivir: an updated review
    Stephen Toovey
    F Hoffmann La Roche Ltd, PBMT Bldg 74 3O Z01 05, CH 4070, Basel, Switzerland
    Adv Ther 29:826-48. 2012
    ..The new data support the findings of the original assessment. Evidence suggests that influenza-related encephalopathies are caused by influenza-induced inflammatory responses, but more work is needed to confirm the underlying mechanisms...
  4. doi request reprint Absence of central nervous system and hypothermic effects after single oral administration of high doses of oseltamivir in the rat
    Christian Freichel
    F Hoffmann La Roche Ltd, Basel, Switzerland
    Basic Clin Pharmacol Toxicol 111:50-7. 2012
    ..In rats, oseltamivir at supratherapeutic doses up to 1000 mg/kg free base did not exert any effects on CNS function or hypothermic effects and led to limited CNS exposure, resulting in large safety margins...
  5. doi request reprint Oseltamivir in seasonal, pandemic, and avian influenza: a comprehensive review of 10-years clinical experience
    James R Smith
    Pharmaceuticals Division, F Hoffmann La Roche Ltd, PBMT Bldg 74 3O Z1 06, CH 4070, Basel, Switzerland
    Adv Ther 28:927-59. 2011
    ..Finally, the article considers the pharmacoeconomics of oseltamivir in comparison with vaccination and usual care regimens, and as a component of pandemic influenza mitigation strategies...
  6. doi request reprint Assessment of neuropsychiatric adverse events in influenza patients treated with oseltamivir: a comprehensive review
    Stephen Toovey
    F Hoffmann La Roche Ltd, Basel, Switzerland
    Drug Saf 31:1097-114. 2008
    ....